S 222611

Drug Profile

S 222611

Alternative Names: S-222611

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Shionogi
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Solid tumours

Most Recent Events

  • 06 Dec 2016 Efficacy and adverse event data from a phase I/II trial in Breast cancer presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS-2016)
  • 11 Nov 2015 Shionogi completes a phase I trial in Solid tumours in England (EudraCT 2009-017817-31)
  • 05 Feb 2014 Phase-I/II clinical trials in Solid tumours in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top